Chemomab Therapeutics (CMMB) Free Cash Flow (2017 - 2023)
Chemomab Therapeutics posted quarterly Free Cash Flow of -$3.7 million for Q4 2023, up 36.23% year-on-year from -$2.7 million in Q4 2022, and up 28.71% on a QoQ basis from -$5.2 million in Q3 2023.
Chemomab Therapeutics (CMMB) has 7 years of Free Cash Flow data on file, last reported at -$3.7 million in Q4 2023.
- For the quarter ending Q4 2023, Free Cash Flow rose 36.23% year-over-year to -$3.7 million; the trailing twelve-month figure through Sep 2024 stood at -$3.7 million (up 85.53% YoY), and the FY2025 full-year result was -$11.1 million, up 27.84% from the prior year.
- Free Cash Flow for Q4 2023 stood at -$3.7 million, up from -$5.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$880000.0 in Q2 2020 and bottomed at -$7.5 million in Q2 2023.
- The 5-year median for Free Cash Flow is -$3.7 million (2019), against an average of -$3.9 million.
- The widest annual swing landed in 2020, when Free Cash Flow surged 77.61%; it then plunged 548.75% in 2021.
- A 5-year view of Free Cash Flow shows it stood at -$5.7 million in 2019, then jumped by 72.52% to -$1.6 million in 2020, then slumped by 94.6% to -$3.0 million in 2021, then slumped by 92.8% to -$5.8 million in 2022, then jumped by 36.23% to -$3.7 million in 2023.
- The last three Free Cash Flow figures came in at -$3.7 million (Q4 2023), -$5.2 million (Q3 2023), and -$7.5 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.72 Mn |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -7.48 Mn |
| Jun 30, 2023 | -7.48 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Dec 31, 2022 | -5.84 Mn |
| Dec 31, 2022 | -5.84 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Jun 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -5.66 Mn |
| Mar 31, 2022 | -3.73 Mn |
| Mar 31, 2022 | -3.73 Mn |
| Dec 31, 2021 | -3.03 Mn |
| Dec 31, 2021 | -3.03 Mn |
| Sep 30, 2021 | -2.58 Mn |
| Sep 30, 2021 | -2.58 Mn |
| Jun 30, 2021 | -5.71 Mn |
| Jun 30, 2021 | -5.71 Mn |
| Mar 31, 2021 | -1.30 Mn |
| Mar 31, 2021 | -1.30 Mn |
| Dec 31, 2020 | -1.56 Mn |
| Dec 31, 2020 | -1.56 Mn |
| Sep 30, 2020 | -921,000.00 |
| Sep 30, 2020 | -921,000.00 |
| Jun 30, 2020 | -880,000.00 |
| Jun 30, 2020 | -880,000.00 |
| Mar 31, 2020 | -1.92 Mn |
| Mar 31, 2020 | -1.92 Mn |
| Dec 31, 2019 | -5.66 Mn |
| Dec 31, 2019 | -5.66 Mn |
| Sep 30, 2019 | -3.76 Mn |
| Sep 30, 2019 | -3.76 Mn |
| Jun 30, 2019 | -3.93 Mn |
| Jun 30, 2019 | -3.93 Mn |
| Mar 31, 2019 | -3.20 Mn |
| Mar 31, 2019 | -3.20 Mn |
| Dec 31, 2018 | -3.92 Mn |
| Dec 31, 2018 | -3.92 Mn |
| Sep 30, 2018 | -6.54 Mn |
| Sep 30, 2018 | -6.54 Mn |
| Jun 30, 2018 | -1.92 Mn |
| Jun 30, 2018 | -1.92 Mn |
| Mar 31, 2018 | -2.68 Mn |
| Mar 31, 2018 | -2.68 Mn |
| Dec 31, 2017 | -1.89 Mn |
| Dec 31, 2017 | -1.89 Mn |